The July 24 event aims to inspire accessible and impactful philanthropy by breaking down barriers to meaningful change.

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following CD19-directed CAR-T, according to results of a phase 1 study.More than 80% ...

This article discusses the DOJ’s growing crackdown on healthcare fraud, focusing on illegal speaker programs like Gilead’s $202 million settlement. It stresses the importance of strong compliance, ...

Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

Dr Reddy’s Laboratories prepares for US market challenges with strategic growth initiatives and strong financial performance in FY25.

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.